Skip to main content

Table 2 Comparisons of the outcomes between PMX-HP and control group in the J-DPC studies and some large-scale studies including RCTs

From: Potential survival benefit and early recovery from organ dysfunction with polymyxin B hemoperfusion: perspectives from a real-world big data analysis and the supporting mechanisms of action

  Length of ICU/R stay (days)/HP stay rate at day 28(%) MV-free days NAD-free days/increasing of BP CHDF-free days 28-day outcome (%)
Iwagami et al. [8] NA NA NA NA (Mortality)
40.2 vs 46
OR 0.76
p = 0.003
Fujimori et al. [11] NA 20 (1–28) vs 14 (0–28)
p < 0.0001
24 (11–26) vs 22 (0–25)
p < 0.0001
24 (9–28) vs 22 (0–28)
p < 0.0001
(Survival rate)
77.9 vs 71.1
OR 1.433
p < 0.0001
Fujimori et al. [10] 9 (5–13) vs 11 (6–13), p = 0.016/81.6 vs 3.4%
HR 1.083
NA NA NA (Survival rate)
69.5 vs 65.4
HR 0.905
p < 0.0001
Fujimori et al. [12] NA 16 (0–23) vs 12 (0–22)
p = 0.0061
24 (15-26) vs
22(0-26)
p = 0.0005
23 (8–25) vs 21 (0–24)
p = 0.0034
(Mortality)
18.6 vs 27.4
p = 0.0008
Dellinger, R. P. et al. [13] /NS mean (SD)
12.7 (10.9) vs 9.8 (10.0)
p = 0.02
mean (SD)
8.1 (16.0) vs 3.9 (14.1), p = 0.02/
NS NS
Klein, D. J. et al. [14] /NS 20 (0.5–23.5) vs 6 (0–20)
p = 0.004
/8 (−0.5–19.5) vs 4 (−4.0–11)
p < 0.05
NS (Mortality)
26.1 vs 36.8, OR 0.52, p = 0.047
Nakamura, Y. et al. [16] 14 (0–22) vs 18 (0–22)
p < 0.045/
NA NA NA (HP mortality)
32.8 vs 41.2
OR 0.681
p = 0.042